Infliximab in treatment of idiopathic refractory childhood pyoderma gangrenosum (PG)

We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much informa...

Descripción completa

Detalles Bibliográficos
Autores principales: Salehzadeh, Farhad, Mohammadikebar, Yusef, Enteshary, Afsaneh, Ghanbarpour, Omid, Mirzarahimi, Mehrdad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6554516/
https://www.ncbi.nlm.nih.gov/pubmed/31239637
http://dx.doi.org/10.2147/BTT.S203753
Descripción
Sumario:We report a case of refractory idiopathic childhood pyoderma gangrenosum in a young boy who had suffered from this disease since 3 years of age. He had unfavorable responses and intermittent relapses under different combinations of cytotoxic and steroid therapies. Although there was not much information available about infliximab use for biologic and childhood pyoderma gangrenosum, eventually we decided to use infliximab in this patient. Infliximab showed a dramatic response and resulted in full recovery during 2 years' follow-up.

Ejemplares similares